MedTrace Logo

Promoting Cervical Cancer Screening Through the Advocacy of Screened Women

NCT04960748 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2022-04-27

No results posted yet for this study

Summary

This study pilots a 7-session group intervention among 40 screened women, 20 of whom will be randomly assigned to take part in the intervention, and 20 to the wait-list control. Assessments will be administered at baseline and month 6 to index participants as well as up to three unscreened female social network members of each index participant (up to 120 total). The primary outcome is CC screening among participating social network members.

Conditions

  • Cervical Cancer Prevention

Interventions

BEHAVIORAL

WOMEN FIGHTING TO STOP CERVICAL CANCER

The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.

Sponsors & Collaborators

  • Makerere University

    collaborator OTHER

  • Rays of Hope Hospice Jinja

    collaborator UNKNOWN

  • African Palliative Care Association

    collaborator UNKNOWN

  • RAND

    lead OTHER

Principal Investigators

  • Rhoda Wanyenze, MD · Makerere University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2022-04-25
Completion
2022-04-25

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04960748 on ClinicalTrials.gov